Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice.

Abstract:

PURPOSE OF REVIEW:We summarize the concept of a locally advanced basal cell carcinoma (laBCC) and present the current consensus definition. We also review the key pieces of primary research undertaken in the past year and how these affect the use of smoothened inhibitors in a clinical setting. RECENT FINDINGS:Medium term follow-up (30 months) of patients treated with vismodegib shows an improvement in response rates for patients with laBCC. The safety profile of vismodegib demonstrated in the original ERIVANCE study has been replicated in a larger patient cohort in a repeat study. Sonidegib is a new smoothened inhibitor currently under investigation for treatment of laBCC, which demonstrates a comparable safety profile to vismodegib. The side-effects of smoothened inhibitors appear related to both dose and duration of treatment. The durability of response to vismodegib is uncertain, but has been observed to last for over a year following discontinuation of treatment. SUMMARY:The understanding of the efficacy and safety of vismodegib has improved since its introduction in 2012. A broadening evidence base supports its use as a valid treatment for laBCC. However, questions remain as to how to integrate its use into existing pathways for treating laBCC and its long-term efficacy.

journal_name

Curr Opin Oncol

authors

Khoo AB,Ali FR,Lear JT

doi

10.1097/CCO.0000000000000259

subject

Has Abstract

pub_date

2016-03-01 00:00:00

pages

180-4

issue

2

eissn

1040-8746

issn

1531-703X

journal_volume

28

pub_type

杂志文章,评审
  • Neuroendocrine tumors of the diffuse neuroendocrine system.

    abstract:PURPOSE OF REVIEW:Neuroendocrine tumors (previously referred to as carcinoids) are ill-understood, enigmatic malignancies that, although slow-growing compared with adenocarcinomas, can behave aggressively. In 2004, they comprised 1.25% of all malignancies; their incidence is increasing by approximately 6% per year. The...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e3282f1c595

    authors: Gustafsson BI,Kidd M,Modlin IM

    更新日期:2008-01-01 00:00:00

  • Vandetanib and the management of advanced medullary thyroid cancer.

    abstract:PURPOSE OF REVIEW:Vandetanib is a small molecule tyrosine kinase inhibitor that has been recently approved as an 'orphan drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). RECENT FINDINGS:MTC is a neuroendocrine malignancy frequently associated with m...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e32835a42b9

    authors: Campbell MJ,Seib CD,Gosnell J

    更新日期:2013-01-01 00:00:00

  • Overcoming key challenges in cancer immunotherapy with engineered T cells.

    abstract:PURPOSE OF REVIEW:A number of clinical trials are currently testing chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered T cells for the treatment of haematologic malignancies and selected solid tumours, and CD19-CAR-T cells have produced impressive clinical responses in B-cell malignancies. Here, we su...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000664

    authors: Arcangeli S,Mestermann K,Weber J,Bonini C,Casucci M,Hudecek M

    更新日期:2020-09-01 00:00:00

  • Primary liver cancers.

    abstract::A review of the recent literature about liver cancers shows the increasing role of hepatitis C as a risk factor for the development of hepatocellular carcinoma. A new discussion has arisen with regard to the association between the use of oral contraceptives and hepatocellular carcinoma. Patients at risk for developin...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199507000-00017

    authors: Weimann A,Oldhafer KJ,Pichlmayr R

    更新日期:1995-07-01 00:00:00

  • Primary thyroid lymphoma: a review of recent developments in diagnosis and histology-driven treatment.

    abstract:PURPOSE OF REVIEW:Primary thyroid lymphoma (PTL) is a rare but clinically important malignancy of the thyroid. This article reviews the diagnosis, histologic subtypes, pathogenesis, and treatment of PTL, with the objective of optimizing diagnosis and management of the disease. RECENT FINDINGS:Recent studies have shed ...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e3283330848

    authors: Graff-Baker A,Sosa JA,Roman SA

    更新日期:2010-01-01 00:00:00

  • Treatment of low-grade pediatric gliomas.

    abstract::The prognosis of pediatric low-grade gliomas is relatively favorable, but residual or unresectable tumors remain a challenge. Conventional radiation therapy is effective but may be associated with unacceptable sequelae in young children. Chemotherapy can delay the need for radiation therapy in young children; however,...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-200005000-00002

    authors: Schmandt SM,Packer RJ

    更新日期:2000-05-01 00:00:00

  • Perspectives for immunotherapy in glioblastoma treatment.

    abstract:PURPOSE OF REVIEW:Avoiding immune destruction is one emerging hallmark of cancer, including glioblastoma. The number of immunotherapy approaches to fight glioblastoma is growing. Here, we review the recent progress in four main areas: dendritic cell immunotherapy, peptide vaccination, chimeric antigen receptors and imm...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000135

    authors: Finocchiaro G,Pellegatta S

    更新日期:2014-11-01 00:00:00

  • Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.

    abstract:PURPOSE OF REVIEW:Increasing attention is being given to personalized medicine in oncology, where therapies are tailored to the particular characteristics of the individual cancer patient. In recent years, there has been greater focus on prostate-specific membrane antigen (PSMA) in prostate cancer (PCa) as a target for...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000277

    authors: Bouchelouche K,Choyke PL

    更新日期:2016-05-01 00:00:00

  • Digital quantification of mutant DNA in cancer patients.

    abstract:PURPOSE OF REVIEW:The accumulation of somatic mutations is the major driving force for tumorigenesis. These mutations uniquely differentiate tumor cells from their normal counterparts. Mutations within tumor cells and mutant DNA released by tumor cells into blood, lymph, stool, tissues and other bodily compartments can...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e328011a8e7

    authors: Diehl F,Diaz LA Jr

    更新日期:2007-01-01 00:00:00

  • Paracrine interactions of cancer-associated fibroblasts, macrophages and endothelial cells: tumor allies and foes.

    abstract:PURPOSE OF REVIEW:Tumor stroma is composed of many cellular subtypes, of which the most abundant are fibroblasts, macrophages and endothelial cells. During the process of tissue injury, these three cellular subtypes must coordinate their activity to efficiently contribute to tissue regeneration. In tumor, this mechanis...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000420

    authors: Ronca R,Van Ginderachter JA,Turtoi A

    更新日期:2018-01-01 00:00:00

  • Cutaneous manifestations of cancer.

    abstract::The appearance of skin lesions in patients with occult or obvious malignancy may be of extreme value in the detection and management of cancer because the skin is readily accessible to examination and biopsy. Examination of the skin of our patients can provide important insights into underlying malignant processes or ...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199903000-00011

    authors: Sabir S,James WD,Schuchter LM

    更新日期:1999-03-01 00:00:00

  • Testicular germ cell tumors.

    abstract:PURPOSE OF REVIEW:An overview of many of the preclinical and clinical developments in germ cell tumors over the past year is presented. RECENT FINDINGS:Recent epidemiologic studies show changes in the ethnic incidence of germ cell tumors; in particular, African-Americans have seen an increase. Additionally, risk facto...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/01.cco.0000219257.37843.ca

    authors: Bridges B,Hussain A

    更新日期:2006-05-01 00:00:00

  • Treatment of adult acute leukemia.

    abstract::In 1996 progress has been made toward a better understanding of acute leukemias, their biology, the effects of different intensity or subtype-specific chemotherapy, and the contribution of bone marrow transplantation. In acute lymphoblastic leukemia, high-dose cytarabine in induction and in postremission treatment imp...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199701000-00004

    authors: Büchner T

    更新日期:1997-01-01 00:00:00

  • Respiratory syncytial virus and other respiratory viruses in the setting of bone marrow transplantation.

    abstract:PURPOSE OF REVIEW:Several epidemiologic studies have enhanced our understanding of the impact of respiratory viruses on bone marrow transplant recipients. RECENT FINDINGS:Respiratory viral infections occur frequently following stem cell transplantation but present atypically. Many patients have asymptomatic infections...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e328324bc1c

    authors: Ison MG

    更新日期:2009-03-01 00:00:00

  • Management of brain metastases in patients with melanoma.

    abstract:PURPOSE OF REVIEW:Melanoma is the third most common metastatic brain tumor in the United States and is a major cause of morbidity and mortality. The development of more effective therapies for melanoma brain metastases is a major unmet clinical need and is summarized in this review. RECENT FINDINGS:Management strategi...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-200403000-00014

    authors: Tarhini AA,Agarwala SS

    更新日期:2004-03-01 00:00:00

  • Immunotherapy-based combinations: an update.

    abstract:PURPOSE OF REVIEW:The advent of immunotherapy significantly improved clinical outcomes in cancer patients, although immune checkpoint blockade (ICB) still lack of efficacy in a consistent proportion of treated patients. The purpose of this article is to review the most innovative and clinically promising ICB-based comb...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000466

    authors: Fucà G,de Braud F,Di Nicola M

    更新日期:2018-09-01 00:00:00

  • Surgical chores and approach in the management of endometrial cancer.

    abstract::Carcinoma of the uterine corpus is the most common malignancy in the female pelvis. Surgical resection and staging are now the accepted approach to therapy, with excellent survival compared with other gynecologic malignancies. Several controversies exist, however, regarding optimal surgical management. Some of these c...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-200209000-00007

    authors: McAlpine JN,Spirtos NM,Chen MD

    更新日期:2002-09-01 00:00:00

  • Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?

    abstract:PURPOSE OF REVIEW:The most common mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is acquisition of the T790M gatekeeper mutation. Third-generation EGFR TKIs irreversibly inhibit EGFR mutants (EGFRm), especially T790M, while sparing wild-type EGFR. There are several ...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000350

    authors: Sun JM,Park K

    更新日期:2017-03-01 00:00:00

  • Corrupt policemen: inflammatory cells promote tumor angiogenesis.

    abstract:PURPOSE OF REVIEW:The last decade has seen a paradigm change in that tumor stroma contributes to malignant tumor progression in a manner comparable to genetic and epigenetic changes within cancer cells. This review summarizes recent novel insights into how inflammatory conditions stimulate the formation and expansion o...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e32831bed7e

    authors: Zumsteg A,Christofori G

    更新日期:2009-01-01 00:00:00

  • Combined targeted therapies in non-small cell lung cancer: a winner strategy?

    abstract:PURPOSE OF REVIEW:Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signalling process leading to cancer cell proliferation and to the neoplastic phenotype suppo...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e328011beec

    authors: Cascone T,Gridelli C,Ciardiello F

    更新日期:2007-03-01 00:00:00

  • Endocrine tumors of the pancreas.

    abstract:PURPOSE OF REVIEW:Neoplasms of the endocrine pancreas, commonly referenced as pancreatic islet cell tumors, are rare, often well differentiated endocrine neoplasms, whose biology remains poorly characterized. This article reviews the current clinical management of pancreatic islet cell tumors and describes the molecula...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,收录出版,评审

    doi:10.1097/01.cco.0000198974.59239.3c

    authors: House MG,Schulick RD

    更新日期:2006-01-01 00:00:00

  • Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.

    abstract:PURPOSE OF REVIEW:Temsirolimus (Torisel) is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The recommended dosage in this indication (175 mg once weekly for 3 weeks and then 75 mg once weekly as maintenance) is higher than that for renal ce...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e32835de8ee

    authors: Bouabdallah K,Ribrag V,Terriou L,Soria JC,Delarue R

    更新日期:2013-03-01 00:00:00

  • High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors.

    abstract::Over the past decade, high-dose chemotherapy followed by autologous bone marrow support (ABMS) has been employed with increasing frequency to treat patients with a variety of solid tumors. This paper explores the rationale and relevant clinical data for the use of this approach to treat patients with breast and ovaria...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199403000-00004

    authors: Shpall EJ,Jones RB,Bearman S

    更新日期:1994-03-01 00:00:00

  • Developments and controversies in the management of noninvasive bladder cancer.

    abstract:PURPOSE OF REVIEW:To summarize recent developments and controversies in the diagnosis and management of nonmuscle invasive bladder cancer (NMIBC). RECENT FINDINGS:The majority of incident bladder cancer diagnoses are noninvasive. The mainstay of diagnosis remains cystoscopy and transurethral resection, with enhanced o...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000067

    authors: Bassett JC,Eifler JB,Resnick MJ,Clark PE

    更新日期:2014-05-01 00:00:00

  • Adjuvant therapy for melanoma.

    abstract::The search for effective adjuvant therapy for melanoma has resulted in the testing of a remarkably broad spectrum of therapeutic agents. Until recently, there was little evidence to suggest a benefit for any adjuvant therapy. The demonstration of activity for adjuvant high-dose interferon alfa in a cooperative group t...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199703000-00015

    authors: Sondak VK,Wolfe JA

    更新日期:1997-03-01 00:00:00

  • Biologic agents as modifiers of chemotherapeutic effects.

    abstract::Recent papers dealing with the effect of biologic response modifiers on the therapeutic activity of anticancer drugs are reviewed. Preclinical findings indicate that both interferons and tumor necrosis factor-alpha are able to synergize with different cytotoxic drugs in increasing both tumor cytotoxicity or cytostasis...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/00001622-199112000-00017

    authors: Parmiani G,Rivoltini L

    更新日期:1991-12-01 00:00:00

  • Cabozantinib as an emerging treatment for sarcoma.

    abstract:PURPOSE OF REVIEW:Sarcomas are a diverse group of rare solid tumors with limited treatment options for patients with advanced, inoperable disease. Cabozantinib is a tyrosine kinase inhibitor currently approved for advanced renal cell, hepatocellular, and medullary thyroid carcinoma. Cabozantinib has potent activity aga...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0000000000000644

    authors: Schöffski P,Blay JY,Ray-Coquard I

    更新日期:2020-07-01 00:00:00

  • Testicular cancer.

    abstract::In testicular cancer epidemiology, the increasing recognition that germinal epithelial atrophy is the final common pathway in the development of this tumor has developed along with reports that elevated follicule-stimulating hormone levels at the time of diagnosis of first tumor correlate with risk of developing a sec...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Oliver RT

    更新日期:1991-06-01 00:00:00

  • Hematopoietic stem cell transplantation for AIDS-related malignancies.

    abstract:PURPOSE OF REVIEW:AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection. In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies. Prior to the advent of effective HIV therapy, stem cell transplantati...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/CCO.0b013e32833d2cf0

    authors: Krishnan A,Forman SJ

    更新日期:2010-09-01 00:00:00

  • Pralatrexate: an emerging new agent with activity in T-cell lymphomas.

    abstract:PURPOSE OF REVIEW:T-cell lymphomas (TCL) represent a particularly poor prognosis subgroup of lymphomas. The goal of this review is to provide emerging information on one agent demonstrating activity in these challenging diseases. Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate c...

    journal_title:Current opinion in oncology

    pub_type: 杂志文章,评审

    doi:10.1097/01.cco.0000245309.74767.20

    authors: O'Connor OA

    更新日期:2006-11-01 00:00:00